The MoneyTree™ Report is a quarterly study of venture capital investment activity in the United States. As a collaboration between PricewaterhouseCoopers and the National Venture Capital Association based upon data from Thomson Reuters, it is the only industry-endorsed research of its kind.
For the most recent quarter's results including VC and company lists, as well as aggregate trend data dating back to 1995, visit our interactive MoneyTree Report site: pwcmoneytree.com
Q2 2013: Slight setback
Second-quarter Technology venture capital investment decreased 14% year-over-year but grew 2% quarter-over-quarter.
The Cleantech industry venture capital funding and volume fell year over year; however, two subsectors - solar energy as well as water and waste management - saw an increase in funding this quarter compared to the same period last year.
Q2 2013: Biotech Boost
US venture capital (VC) funding for the life sciences sector, which includes biotechnology and medical devices, improved dramatically, during the second quarter of 2013. According to the MoneyTree™ Report, venture capitalists invested $1.8 billion in 174 life sciences deals.
With technology and innovation coming of age in many emerging countries, these fast-growing markets are important destinations for private equity. Together with our US MoneyTree™ Report, these reports will help you compare trends in various parts of the world and provide a truly global view of VC/PE investments. The global MoneyTree reports serve as a reliable source of current and recent trends in PE/VC funding for: Israel, India, Russia and China (debuting soon).